Skip to main content
Midas Edge

Coherus Oncology, Inc.

For the period ended Dec 31, 2025. Filed Mar 9, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 9, 2026

CHRS$0.64-21.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity (Deficit

​​​​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · Accumulated · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders'
​ · ​ ​ ​ · Shares · ​ ​ ​ · ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Loss · ​ ​ ​ · Deficit · ​ ​ ​ · Equity (Deficit)
Balances at December 31, 2023​112,215,260​$11​$1,386,312​$(248)​$(1,579,500)​$(193,425)
Net income​—​—​—​—​28,507​28,507
Issuance of common stock upon exercise of stock options​174,651​—​291​—​—​291
Issuance of common stock upon vesting of RSUs​816,876​—​—​—​—​—
Issuance of common stock under the ESPP852,222​—​926​—​—​926
Issuance of common stock - partial payout of 2023 bonus in RSUs​1,976,750​​1​​4,407​​—​​—​​4,408
Issuance of common stock under Sales Agreement, net of issuance costs​650,005​​—​​1,455​​—​​—​​1,455
Taxes paid related to net share settlement of RSUs​(1,071,216)​​—​​(2,476)​​—​​—​​(2,476)
Stock-based compensation expense​—​—​28,351​—​—​28,351
Other comprehensive loss, net of tax—​​—​​—​​(27)​​—​(27)
Balances at December 31, 2024115,614,548​​12​​1,419,266​​(275)​​(1,550,993)​​(131,990)
Net income​—​​—​​—​​—​​168,024​​168,024
Issuance of common stock upon exercise of stock options​35,500​​—​​27​​—​​—​​27
Issuance of common stock upon vesting of RSUs​528,673​​—​​—​​—​​—​​—
Issuance of common stock under the ESPP​542,885​​—​​353​​—​​—​​353
Taxes paid related to net share settlement of RSUs​(201,676)​​—​​(283)​​—​​—​​(283)
Stock-based compensation expense​—​​—​​16,909​​—​​—​​16,909
Issuance of common stock under PIPE Securities, net of issuance costs​4,634,995​​—​​7,894​​—​​—​​7,894
Other comprehensive income, net of tax​—​​—​​—​​80​​—​​80
Balances at December 31, 2025​121,154,925​$12​$1,444,166​$(195)​$(1,382,969)​$61,014
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.